MX2022016466A - Vectores de virus adeno-asociados mejorados para terapia genica. - Google Patents

Vectores de virus adeno-asociados mejorados para terapia genica.

Info

Publication number
MX2022016466A
MX2022016466A MX2022016466A MX2022016466A MX2022016466A MX 2022016466 A MX2022016466 A MX 2022016466A MX 2022016466 A MX2022016466 A MX 2022016466A MX 2022016466 A MX2022016466 A MX 2022016466A MX 2022016466 A MX2022016466 A MX 2022016466A
Authority
MX
Mexico
Prior art keywords
associated virus
gene therapy
therapy vectors
adeno
virus gene
Prior art date
Application number
MX2022016466A
Other languages
English (en)
Inventor
Hanna Lesch
Lionel Galibert
Kari Airenne
Amira Hyvönen
Reetta Eriksson
Justin Darius Albers
Original Assignee
Ferring Ventures Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ferring Ventures Sa filed Critical Ferring Ventures Sa
Publication of MX2022016466A publication Critical patent/MX2022016466A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01—DNA viruses
    • C07K14/015—Parvoviridae, e.g. feline panleukopenia virus, human parvovirus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14151—Methods of production or purification of viral material

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La "MAAP" es una proteína de virus adenoasociada de alrededor de 13 KDa recién descubierta y de origen natural. No es homóloga a las proteínas conocidas. Cuando las células productoras de AAV se cultivan durante más de 24 horas, descubrimos que la inactivación de la traducción de la MAAP completa mejora la productividad de las células productoras transfectadas. Los virus AAV resultantes también son de mejor calidad y más estables. Por lo tanto, nuestros hallazgos proporcionan una forma de mejorar la fabricación industrial de vectores de terapia génica de virus adenoasociados recombinantes.
MX2022016466A 2020-06-25 2021-06-25 Vectores de virus adeno-asociados mejorados para terapia genica. MX2022016466A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063043837P 2020-06-25 2020-06-25
PCT/EP2021/067569 WO2021260204A1 (en) 2020-06-25 2021-06-25 Improved adeno-associated virus gene therapy vectors

Publications (1)

Publication Number Publication Date
MX2022016466A true MX2022016466A (es) 2023-06-15

Family

ID=76829531

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022016466A MX2022016466A (es) 2020-06-25 2021-06-25 Vectores de virus adeno-asociados mejorados para terapia genica.

Country Status (11)

Country Link
US (1) US20230374540A1 (es)
EP (1) EP4172322A1 (es)
JP (1) JP2023531281A (es)
KR (1) KR20230078625A (es)
CN (1) CN116249771A (es)
AU (1) AU2021295718A1 (es)
BR (1) BR112022026292A2 (es)
CA (1) CA3188161A1 (es)
IL (1) IL299380A (es)
MX (1) MX2022016466A (es)
WO (1) WO2021260204A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023178220A1 (en) 2022-03-16 2023-09-21 Regenxbio Inc. Compositions and methods for recombinant aav production
WO2023220591A1 (en) * 2022-05-13 2023-11-16 The Regents Of The University Of California Compositions and methods for enhanced production of adeno-associated virus

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2403867T3 (pl) * 2009-03-04 2019-12-31 Deutsches Krebsforschungszentrum Białko aktywujące składanie (aap) i jego zastosowanie do wytwarzania cząstek parwowirusa zasadniczo składających się z vp3
WO2019016349A1 (en) * 2017-07-20 2019-01-24 Uniqure Ip B.V. PRODUCTION OF ENHANCED VAA CAPSIDS IN INSECT CELLS

Also Published As

Publication number Publication date
IL299380A (en) 2023-02-01
WO2021260204A1 (en) 2021-12-30
CA3188161A1 (en) 2021-12-30
JP2023531281A (ja) 2023-07-21
KR20230078625A (ko) 2023-06-02
US20230374540A1 (en) 2023-11-23
BR112022026292A2 (pt) 2023-03-07
CN116249771A (zh) 2023-06-09
AU2021295718A1 (en) 2023-02-02
EP4172322A1 (en) 2023-05-03

Similar Documents

Publication Publication Date Title
MX2022016466A (es) Vectores de virus adeno-asociados mejorados para terapia genica.
EP4122946A1 (en) Adeno-associated virus vector and use thereof
Van Heeke et al. Expression of human asparagine synthetase in Escherichia coli
EA202190512A1 (ru) Композиции и способы для производства векторов для генной терапии
RU2017142006A (ru) Векторы на основе аденоассоциированных вирусов для лечения мукополисахаридозов
Peng et al. Towards scalable production of a collagen-like protein from Streptococcus pyogenes for biomedical applications
MX2019010275A (es) Novedoso vector del subtipo f del virus adenoasociado (aav) y usos de este.
Gvritishvili et al. Codon preference optimization increases heterologous PEDF expression
ES2503365T3 (es) Método para producir proteínas dependientes de vitamina K biológicamente activas por métodos recombinantes
Pandya et al. Rationally designed capsid and transgene cassette of AAV6 vectors for dendritic cell‐based cancer immunotherapy
DE69941823D1 (de) Eine verbesserte methode zur herstellung und reinigung von adenoviralen vektoren
PT84705B (pt) Processo para a expressao do gene clonado de lisostafina
BR9908018A (pt) Adenovìrus modificado contendo uma proteìna de substituição de fibra
EA202091105A1 (ru) Композиции гуанилатциклазы и способы лечения врожденного амавроза лебера типа 1 (lca1)
PH12021550794A1 (en) Generation of improved human pah for treatment of severe pku by liver-directed gene replacement therapy
Valore et al. Laboratory production of antimicrobial peptides in native conformation
WO2022232327A3 (en) Aav capsids and uses thereof
CN108699511B (zh) 包含过氧蛋白的无血清培养基添加剂组合物及其用途
CO2023017400A2 (es) Producción de vectores de aav recombinantes para tratamiento de distrofia muscular
MX2022007135A (es) Vectores de virus adenoasociados para el tratamiento del síndrome de hunter.
MX2022013504A (es) Composiciones útiles en el tratamiento del trastorno de deficiencia de cdkl5 (cdd).
Lee et al. Efficient production of an engineered apoptin from chicken anemia virus in a recombinant E. coli for tumor therapeutic applications
CN1499980A (zh) 造血干细胞和/或造血前体细胞的增殖和/或分化促进剂
MX2022004345A (es) Construcciones de igf2 variantes.
Dziamałek-Macioszczyk et al. Versatility of USP18 in physiology and pathophysiology